NDASUBCUTANEOUSSOLUTION, EXTENDED RELEASEPriority Review
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
BRIXADI (buprenorphine) by Braeburn Pharmaceuticals is partial opioid agonists [moa]. Approved for opioid use disorder, chronic pain. First approved in 2023.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRIXADI is a subcutaneous, extended-release buprenorphine solution approved in May 2023 for opioid use disorder and other indications. It is a partial opioid agonist that binds to mu-opioid receptors with lower intrinsic activity than full agonists, reducing euphoria and overdose risk. The drug addresses patients with opioid use disorder, chronic pain, and substance use disorders across multiple therapeutic areas.
$363KPart D
Growth6.2 years to LOEEarly-stage growth product with nascent commercial footprint suggests expanding sales team and account manager opportunities as market adoption accelerates.
Mechanism of Action
Partial Opioid Agonists
Pharmacologic Class:
Partial Opioid Agonist
Indications (2)
Clinical Trials (20)
Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic
Started Apr 2026
60 enrolled
Opioid Use Disorder
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
Started Dec 2025
A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine
Started Jan 2025
60 enrolled
Opioid Use Disorder
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Started Jan 2025
32 enrolled
Healthy Volunteer Study
An Exploratory Clinical Study of a Low-dose Buprenorphine Patch for the Treatment of Autism Spectrum Disorders
Started Jan 2025
60 enrolled
Autism Spectrum Disorder
Worked on BRIXADI at Braeburn Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.